GCT accomplished patient enrollment for a Phase II wAMD program

We are delighted to announce patient recruitment completion for two parallel Phase II Age-Related Macular Degeneration studies in EU.

Across 12 participating sites 56 patients were enrolled in 5 months in two studies.

Majority of the patients have now completed the treatment; the remaining patients will finish trial procedures during upcoming weeks.

With the patient PK samples being analyzed, GCT and Sponsor are working closely towards studies’ completion.

 

Image credit: Ralf Roletschek by CC BY-SA 3.0

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

About

GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login

 

GCT

© 2001—2021 Global Clinical Trials, LLC

All rights reserved.